CANCER AS A METABOLIC DISEASE

Mitochondria, glucose, glutamine, ketogenic adaptation, the microbiome and a seven-system functional biology framework

Executive Summary

Cancer is often described through genes: a mutation appears, growth controls fail, and a clone expands. That description is important, but it is incomplete. A cell cannot divide, repair itself, evade immunity, migrate or survive without energy and raw materials. Cancer therefore has a second language: metabolism. In that language, the central questions are simple. Where does the cell get ATP, the usable energy currency? Where does it obtain carbon and nitrogen to build DNA, proteins and membranes? How does it control oxidative stress? How does it keep growing when oxygen or nutrients change? And how does the surrounding tissue, immune system and microbiome alter those answers?

The mitochondrial metabolic theory puts damaged or inefficient mitochondrial respiration near the beginning of the cancer story and proposes that malignant cells compensate by increasing fermentation, particularly from glucose and glutamine. The theory captures several genuine and important observations. Many cancers display high glucose uptake, high lactate production, abnormal mitochondrial structure, altered respiratory-chain function and strong glutamine dependence. Recent work in malignant glioma models also shows that glutamine can help maintain ATP when glucose and oxygen are restricted, consistent with mitochondrial substrate-level phosphorylation. In simple language, a tumour cell may have more than one emergency generator: cytosolic glycolysis can turn glucose into lactate, while mitochondrial reactions can extract usable energy from glutamine even when classical oxidative phosphorylation is constrained.

However, the strongest modern literature also requires an important correction. Cancer is metabolically heterogeneous. Functional mitochondria are essential in many tumours. Human tumours can oxidise glucose, lactate, glutamine, fatty acids and, in some settings, ketone bodies. Some cancers retain substantial oxidative phosphorylation; others switch between fuels depending on oxygen, genotype and nutrient availability. Consequently, “all cancer cells have broken mitochondria” and “cancer cells cannot use ketones” are too absolute. A scientifically stronger model is that malignant cells reprogramme metabolism and exploit whichever pathways best support survival and proliferation in their particular environment.

Ketogenic adaptation is therefore best understood as a change in the host metabolic environment, not as a universal tumour poison. As carbohydrate availability falls and insulin signalling falls with it, the liver increases fatty-acid oxidation and produces ketone bodies, particularly beta-hydroxybutyrate. Over several weeks, many normal tissues increase their capacity to use fatty acids and ketones. Beta-hydroxybutyrate is also a signalling molecule that can affect histone acetylation, oxidative-stress responses and the NLRP3 inflammasome. These are biologically plausible mechanisms through which nutritional ketosis could alter inflammation, redox biology, insulin signalling and the tumour microenvironment.

Yet the human cancer evidence remains far behind the mechanistic story. Controlled trials show that ketogenic diets can reliably change glucose and ketone exposure in many participants, but the available trials are small, heterogeneous and usually short. Systematic reviews do not establish that a ketogenic diet prevents cancer, cures cancer or improves overall survival across cancers. Moreover, preclinical studies identify important exceptions: tumours with active ketone utilisation machinery can sometimes use ketones, and a BRAF V600E melanoma model grew faster in a ketogenic, acetoacetate-rich environment. That does not make ketosis “bad”; it means tumour biology matters and universal claims are unsafe.

The microbiome adds another layer. Ketogenic diets reshape gut microbial communities in ways that are not identical to conventional high-fat diets. Human feeding experiments have shown reduced bifidobacteria and changes in intestinal Th17 immune cells during ketogenic feeding. Other research shows that dietary fibre and microbial short-chain fatty acids support the intestinal barrier and regulate immune function, while secondary bile acids and other microbial metabolites can promote carcinogenic signalling in specific contexts. Therefore a metabolically sound ketogenic pattern cannot be reduced to “eat fat and remove plants.” A low-carbohydrate diet that destroys fermentable-fibre intake, narrows plant diversity and produces constipation may improve one metabolic axis while compromising another.

The practical implication is not a single anti-cancer diet. It is a systems strategy that makes the normal host harder to push toward chronic hyperinsulinaemia, visceral adiposity, inflammatory signalling, circadian disruption, loss of muscle, impaired barrier function and poor mitochondrial flexibility. Seven functional systems provide a useful way to organise that strategy: Energy; Assimilation and Elimination; Cellular Transport; Cellular Communication; Defence; Structure; and Detoxification. This seven-system framework is an organising lens rather than a validated oncology taxonomy, but it prevents a common error: focusing on glucose while ignoring the rest of the biology.

The conclusions in one page

1. Metabolic reprogramming is a core property of cancer, but cancer is not metabolically uniform. Genetics, epigenetics, mitochondrial state, nutrient supply, immunity and the tissue environment interact bidirectionally.
2. The Warburg effect is real: many tumours use high rates of glucose and release lactate even when oxygen is present. It does not prove that every tumour has non-functional mitochondria.
3. Glucose matters as more than fuel. It supplies carbon for nucleotides and lipids, supports NADPH production and is linked to insulin/IGF signalling. Lowering chronic hyperinsulinaemic exposure can change the host growth-signalling environment even when blood glucose remains within a narrow range.
4. Glutamine matters because it supplies carbon, nitrogen and redox support. Some malignant cells can derive ATP-linked energy from glutamine metabolism under constrained conditions. However, dietary glutamine restriction is not a realistic or safe cancer-prevention strategy because the body synthesises glutamine and immune cells depend on it.
5. Ketogenic adaptation lowers reliance on dietary glucose and raises ketones, but ketosis is not synonymous with cancer prevention. Beta-hydroxybutyrate is both a fuel and a signalling metabolite; tumour responses depend on genotype, enzyme expression and microenvironment.
6. The gut microbiome is part of host metabolism. Ketosis changes microbial ecology; fibre-derived short-chain fatty acids, bile-acid metabolism, barrier integrity and immune signalling should be protected rather than ignored.
7. Skeletal muscle is metabolic infrastructure. It disposes of glucose, improves insulin sensitivity, releases signalling molecules and supports functional reserve. Loss of muscle can make the whole metabolic terrain less resilient.
8. Circadian regularity, sleep, physical activity and meal timing influence glucose handling, insulin, immune trafficking and mitochondrial function. These are not lifestyle decorations; they change the biochemical environment in which cells live.
9. “Detoxification” should mean endogenous biotransformation, excretion, redox control, autophagy and mitochondrial quality control—not juices, chelation, megadose supplements or vague cleanses. These pathways can be protective in normal tissue yet may be co-opted by established tumours, so more is not always better.
10. The strongest prevention-oriented position is to improve metabolic health while preserving nutritional adequacy, microbial diversity, muscle and circadian function. A ketogenic diet may be one optional tool for selected people; it is not a universal anti-cancer requirement and no glucose-ketone index threshold has been validated as a cancer-prevention target.

Plain-language bottom line Think of cancer risk biology as a terrain problem. A cell becomes dangerous through accumulated molecular failures, but whether it can thrive also depends on the terrain around it: fuel, hormones, oxygen, immune pressure, inflammation, tissue mechanics, microbial metabolites and the capacity of normal cells to adapt. The goal is not to “starve every cancer cell.” The practical goal is to build a host environment that is metabolically flexible, insulin-sensitive, well-muscled, circadianly stable, microbiome-supportive and less chronically inflamed.

 

Scope, Method and Evidence Boundary

The source channel supplied the thematic map for this paper: mitochondrial dysfunction, fermentation, glucose, glutamine, the glucose-ketone index, press-pulse thinking, ketogenic metabolism, tumour acidity and the idea that cancer can be viewed through energy metabolism. The linked channel is fan-curated rather than an official scientific repository, so audiovisual material was treated as a map of claims, not as evidence. Books and interview scripts were used to identify recurring propositions and terminology. The scientific conclusions in this paper were then filtered through peer-reviewed research in cancer metabolism, mitochondrial biology, microbiology, immunometabolism, ketogenic physiology and human dietary studies.

This is a narrative evidence synthesis, not a formal systematic review. It deliberately excludes medical guidelines and does not reproduce treatment protocols. It also separates levels of evidence. Cell-culture experiments can reveal mechanisms but remove the complexity of blood flow, immunity and whole-body metabolism. Animal experiments add a living organism but do not guarantee human translation. Human feeding studies can establish metabolic effects but may not establish cancer outcomes. Randomised trials are strongest for causation in humans, yet current ketogenic-cancer trials remain small and heterogeneous. These distinctions are carried throughout the paper.

Finally, the phrase “avoiding cancer” is interpreted carefully. No nutritional state can guarantee that cancer will not occur. The seven-system sections therefore describe mechanisms that may reduce biological conditions associated with malignant progression or improve host resilience. They should be read as a framework for risk biology, not as a substitute for diagnosis, screening or treatment.

How to read the evidence labels

• Established mechanism: repeatedly demonstrated molecular or physiological process across multiple models.
• Strong human metabolic evidence: reproducible change in human physiology, even if cancer outcomes are not proven.
• Preclinical anti-cancer evidence: tumour effects shown mainly in cells or animals; promising but not proof in people.
• Emerging or context-dependent: effects vary by tumour type, genotype, diet composition, microbiome or experimental model.
• Not established: plausible idea that currently lacks adequate evidence for a prevention or survival claim.

PART 1: THE METABOLIC ENGINE FOR CANCER

From ATP and mitochondria to glucose, glutamine, lactate and the tumour microenvironment

1. Cancer Is a Growth Programme With an Energy Bill

Every living cell has to solve the same accounting problem. It needs energy to run reactions, carbon to build structures, nitrogen to build amino acids and nucleotides, reducing power to control oxidative chemistry, and a way to remove waste. A normal cell solves this under tight control. Growth signals arrive, nutrients are checked, DNA integrity is monitored, damaged components are recycled, and the cell either divides, pauses or dies.

Cancer uncouples parts of that control. But uncontrolled growth does not remove the accounting problem; it makes the problem larger. A proliferating malignant cell must duplicate DNA, membranes, proteins and organelles. That is why metabolism becomes inseparable from cancer biology. A mutation that says “grow” is useless unless the cell can fund the instruction.

This helps reconcile two apparently competing views. Genetic changes can alter metabolic enzymes, growth pathways and nutrient transport. At the same time, metabolites can alter gene expression, chromatin, redox state and DNA stability. Mitochondrial dysfunction can create reactive oxygen species and metabolite signals that reshape the nucleus. In other words, causality runs both ways. Cancer is not best understood as genes on one side and metabolism on the other. It is a feedback system.

Simple analogy Genes are the software, metabolism is the power supply and raw-material warehouse, mitochondria are both power stations and signalling hubs, and the microenvironment is the city around the factory. Cancer emerges when several layers of control begin reinforcing the wrong programme.

 

The six metabolic jobs a tumour must solve

1. Generate ATP fast enough to stay alive.
2. Supply carbon skeletons to build lipids, nucleotides and proteins.
3. Supply nitrogen for amino acids and DNA bases.
4. Maintain NADPH and glutathione so oxidative stress does not become lethal.
5. Adapt to fluctuating oxygen, acidity and nutrient supply.
6. Communicate with blood vessels, stromal cells and immune cells so the local ecosystem supports survival.

2. Energy 101: Respiration, Glycolysis and Fermentation

ATP is the cell’s spendable energy currency. The fastest way to understand cancer metabolism is to follow how ATP and building blocks are made.

Glycolysis occurs in the cell fluid, outside the mitochondria. One molecule of glucose is split into smaller molecules, producing a small amount of ATP and pyruvate. When pyruvate is reduced to lactate, NAD+ is regenerated so glycolysis can continue. This is fermentation. It is fast but inefficient in ATP per molecule of glucose.

Oxidative phosphorylation occurs mainly across the inner mitochondrial membrane. Carbon from glucose, fatty acids, ketone bodies and some amino acids feeds the tricarboxylic-acid cycle. Electrons then move through the respiratory chain, creating a proton gradient that powers ATP synthase. This process is slower but yields far more ATP from each unit of fuel.

The common oversimplification is that normal cells use mitochondria while cancer cells use glycolysis. Real tumours are more flexible. Many malignant cells run both systems. Some tumour regions are highly glycolytic because oxygen is limited. Other regions oxidise lactate, glutamine or fatty acids. Some cancer stem-like populations depend strongly on oxidative phosphorylation. The ratio changes with genetics, oxygen, nutrient availability and treatment pressure.

Why a cell would choose “inefficient” glycolysis

High-rate glycolysis can still be advantageous when nutrients are abundant. It supplies intermediates for the pentose-phosphate pathway, which produces ribose for nucleotides and NADPH for redox defence. It supplies carbon for amino acids and lipids. It allows rapid ATP production without waiting for mitochondrial throughput. It also generates lactate, which can acidify the microenvironment and influence immune and stromal cells. The important point is that cancer metabolism is organised for growth, not simply for maximum ATP efficiency.

3. The Warburg Effect: What It Proves and What It Does Not

The Warburg effect describes high glucose uptake and lactate production despite oxygen being available. It remains one of the most reproducible metabolic features of many tumours and explains why glucose-based imaging can identify highly glycolytic lesions.

What it proves is that many cancers deliberately route large amounts of glucose through glycolysis. What it does not prove is that their mitochondria are completely non-functional. Human tracer studies show that some tumours oxidise glucose-derived carbon and large amounts of lactate in the tricarboxylic-acid cycle. Many cancers require mitochondrial respiration for biosynthesis, redox balance, signalling and survival.

The better interpretation is therefore functional rather than binary. A malignant cell may have impaired efficiency in one mitochondrial process while preserving others. It may use mitochondrial substrate-level phosphorylation even when respiratory ATP production is limited. It may also retain strong respiration but choose glycolysis because oncogenic signalling, hypoxia or biomass demand makes it advantageous.

Why this nuance matters

If every tumour had the same mitochondrial defect, one metabolic strategy could theoretically work for all cancers. Heterogeneity changes that logic. A metabolic intervention can create pressure, but the tumour may adapt by increasing fatty-acid oxidation, scavenging proteins, using lactate, increasing autophagy or selecting clones with different enzyme expression. This is why “starve cancer of sugar” is a useful doorway into the subject but an inadequate final model.

4. Mitochondria: Damaged Power Stations or Reprogrammed Hubs?

Mitochondria are more than ATP generators. They regulate cell death, iron-sulfur chemistry, one-carbon metabolism, redox balance, calcium signalling, innate immunity and the production of metabolites that can modify DNA and histones. Structural abnormalities of mitochondrial membranes and cristae have been described in many cancers, and respiratory-chain changes are common. These observations support the idea that mitochondrial dysfunction can sit close to the origin or progression of malignancy.

But mitochondrial dysfunction is not one thing. A mitochondrion can consume oxygen yet couple that oxygen inefficiently to ATP production. One complex in the respiratory chain can be impaired while the tricarboxylic-acid cycle continues. Mitochondria can generate biosynthetic intermediates even when their ATP contribution is relatively small. They can also be repurposed to support tumour survival.

Genetic transfer experiments and mitochondrial-DNA depletion studies demonstrate that changing mitochondrial competence can alter tumorigenicity. Conversely, many cancers become less aggressive when functional mitochondrial metabolism is restored or when their mitochondrial supply lines are interrupted. These findings support mitochondria as causal participants. They do not establish that mitochondrial damage is the sole initiating event in every cancer.

A more useful statement Cancer is often a disease of mitochondrial reprogramming and metabolic dependency. In some tumours, respiratory insufficiency may be central. In others, functional mitochondria actively support malignancy. The common feature is not “no mitochondria”; it is abnormal control of energy, biosynthesis and redox.

 

5. Glucose: Fuel, Building Material and Growth Signal

Glucose is attractive to a proliferating cell because it can do several jobs at once. Glycolysis produces ATP quickly. The pentose-phosphate pathway provides ribose for DNA and NADPH for antioxidant defence. Glycolytic intermediates feed amino-acid synthesis, glycerol synthesis and lipid production. Pyruvate can enter mitochondria, while lactate can be exported or later reused.

The host hormonal response to carbohydrate also matters. Insulin is a nutrient-storage hormone, but its signalling network overlaps with growth pathways. Insulin and insulin-like growth factor signalling activate PI3K-AKT-mTOR and related pathways that promote nutrient uptake, protein synthesis and survival. Chronic hyperinsulinaemia therefore creates more than a glucose problem: it creates a growth-signal environment.

This does not mean normal blood glucose “feeds cancer” in a way that can be switched off completely. The body defends blood glucose tightly, and the liver can make glucose from lactate, glycerol and amino acids even when carbohydrate intake is very low. The more realistic metabolic goal is to reduce excessive glucose excursions and chronic insulin demand while improving the ability of muscle and liver to handle nutrients efficiently.

Why refined carbohydrate is different from carbohydrate as a category

A rapidly absorbed, low-fibre carbohydrate load can raise glucose and insulin quickly while contributing little satiety or microbial substrate. A fibrous plant food arrives with cellular structure, water, micronutrients and fermentable substrates. The host and microbiome therefore experience different signals even when both foods contain carbohydrate. Cancer metabolism research does not justify treating every gram of carbohydrate as biologically identical.

6. Glutamine: The Second Major Metabolic Currency

Glutamine is the most abundant amino acid in human blood and tissues. It carries both carbon and nitrogen. That makes it extraordinarily useful to proliferating cells. Its nitrogen can help build nucleotides and amino sugars. Its carbon can refill the tricarboxylic-acid cycle, a process called anaplerosis. It can support glutathione synthesis and redox control. In many tumours, glutamine metabolism becomes a major survival pathway.

Recent malignant glioma experiments add a particularly important piece. When glucose was absent and oxygen was severely limited, glutamine still helped maintain ATP content. The proposed mechanism is mitochondrial substrate-level phosphorylation: ATP or GTP is generated directly at a tricarboxylic-acid-cycle step rather than through the respiratory chain. Succinate released from the cells provided a biochemical footprint consistent with that pathway. In plain language, part of the mitochondrion can function like a small fermentation engine even when classical respiration is constrained.

The result is important but must not be overgeneralised. These experiments used defined glioma cell systems. They strengthen the case that glutamine can be an energy-supporting fermentable substrate in malignant glioma, but they do not prove that every human tumour is driven by the identical mechanism.

Why “stop eating glutamine” does not work

Glutamine is not like dietary sugar. Skeletal muscle, lung and other tissues manufacture it, and the body maintains a large circulating pool. Immune cells, intestinal cells and healing tissues use glutamine heavily. Removing glutamine-rich foods does not selectively deprive a tumour; it can instead reduce protein quality and lean-mass support while the body continues synthesising glutamine.

Therefore the mechanistic finding “glutamine matters to cancer” should not be converted into the dietary instruction “restrict protein or glutamine.” Pharmacological glutamine-pathway inhibition is a separate research question and belongs to oncology research, not self-directed prevention.

7. Lactate, Acidity, Hypoxia and Metabolic Cooperation

Lactate was once treated as metabolic waste. That view is obsolete. Lactate moves carbon between cells and organs. Some human tumours take up circulating lactate and oxidise it in mitochondria. Within one tumour, glycolytic cells can export lactate while better-oxygenated cells import and burn it. This creates metabolic cooperation.

At the same time, high lactate production contributes to extracellular acidity. A more acidic tumour microenvironment can promote invasion, alter extracellular matrix behaviour and suppress parts of anti-tumour immunity. Hypoxia adds another signal by stabilising transcription factors that increase glycolysis, angiogenesis and survival pathways.

This is why tumour metabolism should be viewed as an ecosystem. Glucose, glutamine, lactate, oxygen, blood flow and immune function interact. Restricting one input may change the ecosystem, but the response depends on what alternative pathways remain available.

PART II: KETOGENIC ADAPTATION AND THE MICROBIOME

What changes when the host shifts from frequent glucose dependence toward fat and ketone metabolism

8. Nutritional Ketosis Is a State; Keto-Adaptation Is a Process

Nutritional ketosis begins when liver ketone production rises enough for beta-hydroxybutyrate and acetoacetate to become meaningful circulating fuels. This usually happens when carbohydrate availability and insulin are low enough to release fatty acids from adipose tissue and increase liver fat oxidation. A blood ketone reading can change within hours. Keto-adaptation takes longer.

During adaptation, muscle increases fat oxidation, the liver becomes efficient at ketogenesis, transporters and enzymes involved in ketone use change, and the brain gradually uses more ketones. Glycogen is still available, but fuel selection shifts. Human studies of chronic ketosis and highly keto-adapted endurance athletes show markedly increased rates of fat oxidation. This is metabolic flexibility in one direction: the host becomes better able to function with less incoming carbohydrate.

The distinction matters because an overnight fast that produces a small ketone reading is not the same metabolic condition as several weeks of sustained low-carbohydrate adaptation. Likewise, very high ketones are not necessarily better. The biology depends on energy balance, protein intake, micronutrient status, hydration, exercise and the composition of dietary fat and fibre.

The main whole-body changes

• Lower insulin exposure and lower suppression of adipose-tissue lipolysis.
• Higher delivery of fatty acids to liver and muscle.
• Higher hepatic production of beta-hydroxybutyrate and acetoacetate.
• Lower reliance on dietary glucose, with continued endogenous glucose production for glucose-dependent tissues.
• Altered water and sodium handling, especially early in adaptation.
• Changed substrate use during exercise, with greater fat oxidation and potentially reduced economy for repeated very-high-intensity work in some people.
• Altered gut microbial ecology because the diet changes both macronutrient substrate and host ketone exposure.

9. Beta-Hydroxybutyrate: More Than a Fuel

Beta-hydroxybutyrate is chemically small but biologically busy. It can be oxidised for energy by many normal tissues. It also acts as a signalling metabolite. Experimental work shows that it can inhibit selected histone deacetylases, changing gene expression linked to oxidative-stress resistance. It can suppress activation of the NLRP3 inflammasome, a molecular platform that drives inflammatory cytokine production. It can signal through cell-surface receptors and alter redox state.

These observations create plausible mechanisms by which ketosis could change the host environment around a tumour: lower insulin, different inflammatory tone, altered oxidative stress and a different fuel mix. In mouse tumour models, ketogenic feeding or beta-hydroxybutyrate has sometimes improved T-cell-dependent anti-tumour responses.

But signalling molecules rarely have one universal effect. Concentration, tissue, genotype and timing matter. Beta-hydroxybutyrate cannot be assumed to be anti-cancer simply because it suppresses one inflammatory pathway. The same principle applies to every metabolite in this paper: context decides whether a pathway protects the host, protects the tumour or does both at different stages.

10. The Microbiological Impact of Ketogenic Adaptation

The gut microbiome is a metabolic organ made of thousands of microbial species and millions of microbial genes. These microbes digest compounds that human enzymes cannot, transform bile acids, produce short-chain fatty acids, modify xenobiotics and train immune cells. Any diet that sharply changes carbohydrate, fat and fibre supply will therefore change microbial ecology.

In a controlled human feeding study, a ketogenic diet altered the gut microbiome in a pattern distinct from a conventional high-fat diet. Bifidobacteria decreased, and ketone bodies themselves inhibited bifidobacterial growth. When the keto-associated microbial community was studied experimentally, intestinal Th17 immune cells decreased. The important message is not that lower bifidobacteria is automatically good or bad. It is that ketones and carbohydrate restriction directly change the microbial-immune conversation.

This has major implications for cancer-risk biology because the microbiome influences barrier integrity and immune tone. A disrupted barrier can increase exposure to microbial products that promote systemic inflammation. By contrast, microbial fermentation of selected fibres produces acetate, propionate and butyrate. Butyrate is a preferred fuel for healthy colon cells and can strengthen barrier function, regulate immune cells and inhibit histone deacetylases. In colorectal-cancer models, butyrate biology is strongly context-dependent, but a chronically fibre-depleted colon loses a major microbial metabolic pathway.

Butyrate is not beta-hydroxybutyrate

The names sound similar, which causes confusion. Butyrate is mainly produced by gut microbes fermenting dietary fibre. Beta-hydroxybutyrate is mainly produced by the liver from fatty acids during fasting or carbohydrate restriction. Both can influence histone deacetylases, but they arise in different compartments and do not make fibre and ketosis interchangeable.

Bile acids, protein fermentation and the colon

High-fat feeding changes bile-acid flow because bile is needed to emulsify fat. Gut microbes then convert primary bile acids into secondary bile acids. Some secondary bile acids can damage DNA, alter membranes and promote inflammatory or proliferative signalling in experimental models. High amounts of poorly digested protein reaching the colon can also produce ammonia, phenols, indoles and other metabolites whose effects depend on dose and context.

This is why a well-formulated low-carbohydrate pattern should not be equated with unlimited processed meat, butter and cheese plus minimal plants. If carbohydrate restriction is used, preserving non-starchy vegetables, nuts, seeds, herbs, spices and other tolerated sources of fermentable substrate helps protect the microbial side of the system.

Microbiome principle Do not trade lower glucose exposure for a fibre-starved gut. A metabolically intelligent low-carbohydrate diet should lower refined carbohydrate while retaining microbial substrate diversity, bowel regularity and nutritional adequacy.

 

11. Why “Cancer Cannot Use Ketones” Is Too Simple

The ketogenic anti-cancer hypothesis is often presented as a clean fuel mismatch: normal cells can use ketones, cancer cells cannot, so lowering glucose while raising ketones selectively stresses cancer. This pattern is plausible in tumours with poor ketone-oxidation capacity and has been demonstrated in several preclinical models.

However, cancers differ in the enzymes needed to oxidise ketone bodies. Tumour models with low expression of key ketolytic enzymes have shown greater sensitivity to ketogenic feeding, whereas tumours with higher ketone-utilising capacity have sometimes grown faster. In another model, acetoacetate enhanced signalling through the BRAF V600E oncogene and a ketogenic diet accelerated melanoma xenograft growth.

Other tumour systems can use beta-hydroxybutyrate or acetoacetate as carbon or signalling molecules. These exceptions do not erase the large body of anti-tumour preclinical ketogenic research. They change the claim from universal to conditional.

The clinically important inference

A prevention strategy should not chase ketosis for its own sake. The more defensible targets are improved insulin sensitivity, reduced hyperinsulinaemia, lower refined-carbohydrate exposure, healthy body composition, preserved muscle, low chronic inflammation and a resilient microbiome. Ketosis may achieve several of those goals for some people, but similar host improvements can be achieved through other whole-food dietary patterns.

12. What Human Ketogenic-Cancer Research Actually Shows

Human evidence is growing, but it remains immature compared with the mechanistic literature. Systematic reviews have included several hundred cancer patients across different tumour types, diet formulations and treatment settings. The diets generally produce ketosis when adherence is sufficient. Some trials report lower glucose, insulin or body fat. Feasibility varies widely, and dropout can be substantial because the diet is restrictive or because advanced cancer itself makes eating difficult.

The major limitation is that metabolic outcomes are not cancer outcomes. Lower glucose or higher ketones demonstrate that the intervention changed host metabolism. They do not prove slower tumour growth or longer survival. Randomised-trial meta-analysis to date has not established a definitive anti-tumour effect. Glioma studies remain small, and some of the most striking long-survival reports come from highly selected adherent patients, case reports or uncontrolled cohorts. These observations can generate hypotheses but cannot establish causation.

Therefore the evidence ladder is asymmetric: the metabolic rationale is strong; preclinical tumour effects are substantial in several models; human feasibility is demonstrated; but prevention and survival benefits remain unproven across cancers.

Evidence boundary Nutritional ketosis is a measurable human metabolic state. It is not a validated cancer-prevention state. No blood beta-hydroxybutyrate level and no glucose-ketone index threshold has been proven to prevent cancer in healthy humans.

 

PART III: THE SEVEN FUNCTIONAL SYSTEMS

A practical systems-biology lens for reducing metabolic dysfunction while preserving host resilience

The following seven systems are used as an organising framework: Energy; Assimilation and Elimination; Cellular Transport; Cellular Communication; Defence; Structure; and Detoxification. This framework is not a recognised staging system or a validated cancer-risk score. Its value is practical: it prevents metabolic health from being reduced to one glucose reading or one diet. Each system asks three questions: Why does this biology matter? What tends to go wrong? How can normal physiology be supported without making unproven cancer claims?

13. System One — Energy

Why it matters

Energy is the foundation because every other system spends ATP. Mitochondria must make energy while controlling reactive oxygen species, maintaining membrane potential and supplying biosynthetic intermediates. Metabolic flexibility means being able to move between glucose and fat use without large, prolonged excursions in glucose, insulin or free fatty acids.

Chronic energy surplus, visceral fat accumulation and insulin resistance create a biochemical environment with more insulin, more inflammatory signalling and altered lipid flux. The issue is not that insulin “causes cancer” by itself. Rather, hyperinsulinaemia can amplify growth pathways while adipose dysfunction supplies cytokines, lipids and endocrine signals that interact with tumour biology.

What to support

• High insulin sensitivity: muscle and liver respond strongly to ordinary insulin signals, so the pancreas does not need to maintain chronically high insulin output.
• Metabolic flexibility: the ability to use carbohydrate when needed and increase fat oxidation when carbohydrate intake falls.
• Mitochondrial quality: regular turnover of damaged mitochondria and maintenance of respiratory capacity.
• Low chronic energy surplus: enough energy for function and recovery without continuous storage pressure.
• Adequate protein and micronutrients: energy restriction should not be achieved by sacrificing lean tissue.

How to implement the biology

Start with food quality before macronutrient ideology. Remove or sharply reduce liquid sugar, refined starches and ultra-processed snack foods that make high energy intake easy and satiety weak. Build meals around protein, minimally processed fats and fibrous whole foods. For people who respond well to lower carbohydrate, carbohydrate can be reduced progressively until appetite, glucose control and energy are stable. Nutritional ketosis is optional rather than mandatory.

Movement after meals is a simple metabolic lever because contracting muscle can increase glucose uptake independently of insulin. Resistance exercise increases the amount and quality of muscle available to dispose of glucose. Aerobic work increases mitochondrial density and oxidative capacity. Together they change the host environment more broadly than carbohydrate restriction alone.

Avoid the trap Do not use high ketones as a proxy for mitochondrial health. High ketones can coexist with low fitness, low muscle mass, poor sleep or a fibre-poor diet. Measure the system, not one metabolite.

 

14. System Two — Assimilation and Elimination

Why it matters

Assimilation is the conversion of food into absorbable nutrients and microbial metabolites. Elimination is the removal of what the body does not need through stool, urine, breath and other routes. The gut sits at the centre because it is simultaneously a digestive tube, immune organ, endocrine organ and microbial ecosystem.

A healthy intestinal barrier selectively allows nutrients through while limiting uncontrolled movement of microbial products. The mucus layer, tight junctions, immune cells and microbiota cooperate to maintain that barrier. Fibre fermentation produces short-chain fatty acids that feed colonocytes and regulate immunity. Bile acids carry messages through nuclear and cell-surface receptors. Transit time influences how long microbial and dietary metabolites contact the colon wall.

How low-carbohydrate eating can go wrong

A person can achieve perfect blood ketones while eating too little fibre, drinking too little fluid and developing constipation. That matters because a diet is not metabolically successful if it improves one biomarker while degrading intestinal function. Very low plant diversity can reduce substrate for butyrate-producing microbes. High fat intake can also alter bile-acid exposure, while excessive processed meat may alter colonic nitrogen and haem chemistry.

How to support this system

• Keep non-starchy vegetables, herbs and spices as a routine part of meals rather than treating all plant carbohydrate as an enemy.
• Use nuts and seeds as low-carbohydrate sources of fibre and polyphenols when tolerated.
• Increase fermentable fibre gradually; abrupt large increases can worsen bloating in susceptible people.
• Protect bowel regularity with adequate fluid, electrolytes, movement and sufficient food volume.
• Use fermented foods as foods, not as a promise to permanently “seed” the microbiome; microbial effects are individual and transient.
• Avoid assuming that an over-the-counter probiotic automatically improves cancer-related immunity. Human data are strain-, host- and context-specific.

15. System Three — Cellular Transport

Why it matters

Cells live in a transport network. Blood delivers oxygen, glucose, amino acids, fatty acids, hormones and immune cells. Lymphatic flow returns fluid and carries immune information. Membrane transporters determine which fuels enter a cell. Monocarboxylate transporters move lactate and ketones. Glucose transporters control glucose entry. Amino-acid transporters help determine glutamine flux.

Tumours exploit this network by inducing angiogenesis and by changing transporter expression. Poorly organised tumour vessels create zones of hypoxia and acidity, which can select more aggressive phenotypes. Meanwhile, normal vascular health influences insulin delivery, skeletal-muscle perfusion and the ability to clear metabolites after exercise or meals.

How to support normal transport biology

Regular aerobic and resistance exercise are powerful because they improve endothelial function, capillary density in active tissue and mitochondrial oxygen use. Breaking up prolonged sitting maintains repeated muscle contractions and blood flow. Adequate hydration supports plasma volume, but excess water cannot compensate for poor vascular function.

Breathing practices may change autonomic tone and carbon-dioxide handling, but there is no evidence that breathing techniques can “oxygenate a tumour away.” Similarly, hyperbaric oxygen is a specialised experimental or clinical intervention, not a self-directed prevention tool. The prevention-oriented target is normal cardiorespiratory fitness and vascular function.

16. System Four — Cellular Communication

Why it matters

Cells make decisions by reading signals. Insulin says that energy is available. mTOR integrates amino acids, insulin and growth factors and promotes biosynthesis. AMPK senses low cellular energy and shifts the cell toward conservation and repair. Cortisol coordinates stress responses. Circadian clocks tell tissues when to anticipate feeding, activity and rest. Cytokines communicate immune state.

Cancer often hijacks these same pathways. PI3K-AKT-mTOR signalling is frequently activated. Circadian disruption can alter DNA repair, immune trafficking and metabolic gene expression. Chronic stress does not mechanically “cause cancer,” but repeated sympathetic and endocrine signalling can worsen sleep, glucose regulation and inflammatory tone.

How to reduce signalling noise

• Keep sleep and wake time reasonably consistent so central and peripheral clocks receive a stable daily signal.
• Seek bright natural light early in the active period and lower light exposure late in the evening.
• Avoid making the largest, most refined meal the final event before sleep; late nutrient delivery can oppose circadian metabolic programming.
• Use exercise as a timing signal as well as a fitness intervention.
• Build meals that produce satiety rather than continuous grazing. Constant feeding keeps nutrient-sensing pathways repeatedly activated.
• Use slow breathing, meditation or other down-regulation practices for stress physiology when helpful, but treat them as autonomic tools rather than direct anti-cancer therapies.

17. System Five — Defence

Why it matters

The immune system is continuously sampling abnormal cells. Natural killer cells, cytotoxic T cells, macrophages, dendritic cells and other populations can identify and remove transformed cells. Established tumours survive partly by suppressing, excluding or exhausting these immune responses.

Metabolism and immunity are inseparable. Activated immune cells change their fuel use dramatically. T cells need glucose and amino acids during proliferation. Tumours can compete for glucose and glutamine, generate lactate and acidity, and create a microenvironment that weakens immune function. This is one reason that crude nutrient-starvation strategies can backfire: the host immune system may need the same substrate being targeted.

How the microbiome enters defence

Microbial metabolites shape immune cell development and barrier immunity. Short-chain fatty acids can support regulatory and epithelial programmes, while microbial products crossing a damaged barrier can create chronic inflammatory signalling. Human immunotherapy studies also show that dietary fibre and microbial composition correlate with treatment response, although treatment response is not the same question as prevention.

How to support host defence biology

• Avoid chronic underfeeding and protein deficiency; immune surveillance is metabolically expensive.
• Preserve muscle and physical fitness because exercise changes immune trafficking and inflammatory signalling.
• Prioritise sleep regularity; circadian timing strongly affects innate and adaptive immune function.
• Protect the gut barrier through dietary fibre diversity and by avoiding unnecessary disruption of the microbiome.
• Reduce chronic drivers of sterile inflammation such as visceral adiposity, smoking exposure and repeated metabolic overload.
• Do not equate immune stimulation with immune health. A balanced, well-regulated response is more useful than indiscriminately “boosting immunity.”

18. System Six — Structure

Why it matters

Structure sounds mechanical, but mechanics are biochemical. Skeletal muscle is a glucose sink, an amino-acid reserve and an endocrine organ that releases myokines during contraction. Bone, fascia and extracellular matrix transmit forces. Cells sense tissue stiffness through integrins, focal-adhesion kinases and YAP/TAZ signalling, which can alter proliferation and metabolism.

Tumour tissue is often mechanically abnormal. Fibrosis, collagen cross-linking and matrix stiffness can promote invasive behaviour and glycolytic reprogramming. This does not mean stretching softens cancer. It means the physical microenvironment is part of cell signalling.

Muscle as anti-fragility infrastructure

For the host, maintaining muscle may be one of the most practical ways to improve metabolic resilience. More functional muscle increases glucose disposal capacity, improves insulin sensitivity, supports mobility and creates reserve against illness. Resistance training also sends repeated anabolic signals to muscle rather than leaving dietary amino acids to circulate in a sedentary system.

A practical structure-first routine contains repeated whole-body resistance work, daily movement through a broad range of motion and enough aerobic activity to maintain cardiorespiratory capacity. The precise programme can vary. The biological target is preserved strength, muscle mass, mitochondrial function and movement capacity across ageing.

19. System Seven — Detoxification

What the word should mean

“Detoxification” becomes unscientific when it means a juice cleanse or a supplement stack. In physiology, it can be defined precisely: enzymes transform foreign chemicals and endogenous waste, transporters move them, the liver and kidneys process them, bile and urine excrete them, antioxidants control reactive chemistry, and autophagy removes damaged cellular components. The gut microbiome can activate, deactivate or transform many compounds before or after the liver handles them.

Phase I enzymes often oxidise or modify compounds. Phase II enzymes conjugate them with groups that make excretion easier. Phase III transporters move products across membranes. The Nrf2 pathway coordinates many antioxidant and detoxification genes. Mitochondrial quality control removes damaged mitochondria through mitophagy.

Why “more detox” is not always better

Several protective pathways are double-edged once a tumour exists. Nrf2 can protect normal cells from carcinogens, yet persistent Nrf2 activation in established tumours can increase antioxidant capacity and treatment resistance. Autophagy can remove damaged organelles and suppress early tumorigenesis, yet established cancers can use autophagy to survive nutrient stress. This is another reason that prevention biology and cancer-treatment biology cannot be collapsed into one supplement protocol.

How to support the system without pseudoscience

• Reduce avoidable exposure before trying to “detox” exposure after the fact. Less smoke, solvent, combustion product and unnecessary chemical load means less work for biotransformation systems.
• Maintain adequate protein because conjugation and antioxidant systems depend on amino acids; aggressive protein restriction can work against normal detoxification capacity.
• Eat a range of plant compounds and sulphur-containing foods if tolerated; many food phytochemicals influence endogenous stress-response pathways, but higher dose is not automatically better.
• Maintain bowel regularity because biliary excretion ultimately depends on intestinal elimination.
• Protect liver and kidney function through metabolic health rather than unproven cleanses.
• Use supplements to correct defined needs, not to force chronic activation of a pathway that may have context-dependent effects.

PART IV: FROM MECHANISM TO PRACTICE

A research-informed framework for improving the host metabolic terrain without pretending that one diet can prevent every cancer

20. The Metabolic Terrain Strategy

The practical objective is to make normal physiology resilient and malignant metabolism less advantaged. That means reducing chronic growth-signal excess without undernourishing the host; improving insulin sensitivity without losing muscle; lowering refined carbohydrate without starving the microbiome; encouraging mitochondrial adaptation without assuming every ketone is protective; and reducing chronic inflammation without suppressing necessary immune responses.

The following sequence is intentionally conservative. It is not a cancer-treatment protocol. It is a way to organise metabolic-health behaviours that are supported by human physiology and mechanistic cancer research.

Step 1 — Remove the metabolic noise

• Eliminate or sharply reduce sugar-sweetened drinks and refined snack foods. These are the easiest sources of rapid glucose exposure without meaningful satiety.
• Reduce foods engineered to combine refined starch, sugar, fat and salt in ways that promote passive overconsumption.
• Consolidate eating into deliberate meals rather than continuous grazing when this can be done comfortably and without under-eating.
• Keep alcohol low because it adds metabolic load, alters liver redox and can displace nutrient-dense food. No amount should be viewed as an anti-cancer tool.
• Avoid smoking and combustion exposure; reducing carcinogen exposure has far stronger biological logic than trying to compensate later with “detox” products.

Step 2 — Build meals that protect both metabolism and microbiology

Use protein as the structural anchor of the meal, then add non-starchy vegetables and other fibre-rich whole foods, followed by minimally processed fats. The exact carbohydrate amount can vary with insulin sensitivity, activity and personal response. A person who needs a ketogenic level of carbohydrate to control appetite or glycaemia can still preserve vegetables, nuts, seeds, herbs and fermented foods.

Fat quality matters. A ketogenic diet based mainly on olive oil, nuts, seeds, avocado, fish, eggs and minimally processed animal foods is biologically different from one dominated by processed meat, butter, cream and packaged “keto” products. Both can produce ketones, but they do not create the same lipid, bile-acid or microbial environment.

Step 3 — Make muscle a daily glucose sink

Walking after meals is a low-cost way to redirect incoming glucose into working muscle. Resistance training provides a larger, longer-term sink by preserving or increasing muscle mass. Aerobic training increases mitochondrial content and fat-oxidation capacity. The useful combination is therefore not “cardio or weights” but both, with daily low-intensity movement filling the space between sessions.

For implementation, a short walk after one or more meals, two or three whole-body resistance sessions spread through the week, and repeated aerobic work at a conversational intensity are practical starting structures for many healthy adults. These numbers are examples for implementation, not cancer-specific therapeutic doses. Capacity, age, medical status and recovery should determine progression.

Step 4 — Stabilise circadian timing

• Anchor waking time and obtain outdoor light early in the active day.
• Put the bulk of physical activity and feeding in the biological daytime when possible.
• Finish the final substantial meal far enough before sleep that digestion is not the dominant night-time signal.
• Protect darkness and temperature at night to support consolidated sleep.
• Use a consistent rhythm on most days; circadian systems respond to repetition more than perfection.

Step 5 — Protect the microbial ecosystem

Track bowel function as seriously as blood glucose. If carbohydrate restriction produces constipation, very low stool volume or shrinking plant diversity, the diet needs redesign. Increase tolerated low-carbohydrate fibre sources gradually. Rotate plant foods rather than eating the same two vegetables every day. Use whole foods before powders when possible. The goal is not maximal bacterial diversity at any cost; it is a stable barrier-supportive ecosystem with adequate microbial fermentation and comfortable transit.

Step 6 — Consider ketosis as an optional metabolic tool

For a generally healthy adult who chooses nutritional ketosis for metabolic reasons, the most defensible approach is gradual carbohydrate reduction while keeping protein adequate and improving food quality. Measure whether the intervention improves the intended host outcomes: appetite control, glucose stability, waist, energy, sleep and exercise recovery. A blood beta-hydroxybutyrate value can confirm ketosis, but chasing higher numbers has no proven prevention advantage.

A glucose-ketone index can describe the relationship between glucose and ketones and can be useful in research. It should not be treated as a validated cancer-prevention score. There is no established evidence that a healthy person must maintain a GKI below 2, 1 or any other threshold to avoid cancer.

Step 7 — Reassess the whole system

A successful metabolic strategy should improve several systems simultaneously. Hunger becomes easier to regulate. Energy is steady. Exercise capacity is preserved or improves. Strength does not fall. Sleep is stable. Bowel function remains comfortable. Glucose regulation improves. The diet remains nutritionally complete and socially sustainable.

If one target improves while three others deteriorate, the strategy needs adjustment. A lower glucose reading is not worth progressive muscle loss. Ketosis is not worth chronic constipation. Weight loss is not automatically beneficial if it is mostly lean tissue. Systems thinking means watching trade-offs.

21. A Seven-System Daily and Weekly Checklist

Daily

• Energy: eat minimally processed meals that control appetite and avoid repeated large glucose-insulin excursions.
• Assimilation/elimination: include tolerated fibre-rich plants and monitor stool regularity.
• Cellular transport: move frequently and avoid long uninterrupted sedentary periods.
• Cellular communication: keep light, feeding and sleep timing reasonably consistent.
• Defence: sleep enough for recovery and avoid chronic underfeeding.
• Structure: use your muscles every day, even if formal strength training occurs only on selected days.
• Detoxification: reduce exposure rather than trying to neutralise it later; support ordinary liver, kidney and bowel physiology.

Weekly

• Perform repeated resistance exercise covering the major movement patterns.
• Accumulate aerobic work at an intensity that can be sustained and recovered from.
• Include some higher-intensity work only if fitness, recovery and medical context make it appropriate.
• Review food diversity: have plant foods, herbs, spices, nuts and seeds narrowed unnecessarily?
• Review recovery: is sleep, strength, mood or exercise performance declining?
• Review metabolic goals: is the intervention improving function, not merely producing a lower scale weight or higher ketone reading?

22. Biomarkers: What They Can Tell You and What They Cannot

Biomarkers are useful when they answer a question. They become misleading when one number is promoted as a complete description of health.

Fasting glucose shows one moment in glucose regulation but can be normal while insulin is high. Fasting insulin adds information about the amount of hormonal effort required to maintain glucose. Glycated haemoglobin estimates longer-term glucose exposure but is influenced by red-cell biology. Triglycerides, HDL and waist circumference provide additional clues about metabolic state. Continuous glucose monitoring can reveal meal-to-meal responses but can also create unnecessary anxiety when small physiological fluctuations are overinterpreted.

Blood beta-hydroxybutyrate confirms nutritional ketosis. It does not measure tumour metabolism. GKI combines glucose and ketone concentrations into one ratio, which can be useful for research adherence, but no prospective evidence validates a prevention threshold in healthy people.

Inflammatory markers can identify systemic inflammation but are nonspecific. Stool microbiome tests can describe sampled organisms or genes but do not yet provide a validated “anti-cancer microbiome score.” The most useful measurements therefore remain those tied to a clear decision rather than those that merely generate more data.

23. The Most Common Metabolic-Cancer Myths

“Cancer is purely genetic.” Too narrow. Genetic and epigenetic alterations are central, but metabolic reprogramming, mitochondria, immunity, microbiota and tissue ecology are also causal participants.

“Cancer is purely metabolic.” Also too narrow. Some metabolic abnormalities can be upstream, others downstream, and many are reinforced by oncogenic mutations. A single-origin theory does not explain every tumour.

“All cancer mitochondria are broken.” False as a universal statement. Mitochondrial structure and function are often abnormal, yet many tumours require functional oxidative metabolism.

“Sugar feeds cancer, so zero carbohydrate prevents cancer.” Glucose is important, but the body makes glucose even during carbohydrate restriction, and tumours can use multiple substrates. Zero carbohydrate has not been proven to prevent cancer.

“Glutamine feeds cancer, so eat less protein.” Mechanistically wrong as a prevention strategy. The body maintains glutamine and immune cells require it. Protein restriction can reduce lean mass and resilience.

“Cancer cells cannot use ketones.” Not universally true. Ketone utilisation varies by tumour type and enzyme expression; some preclinical tumours use ketones or respond adversely to ketogenic conditions.

“If ketones are high, metabolism is healthy.” No. Ketones are one signal. Muscle, fitness, sleep, bowel function, nutrient adequacy, insulin sensitivity and lipid response still matter.

“Keto automatically improves the microbiome.” No. It changes the microbiome. Whether the net effect is beneficial depends partly on fibre, fat quality, protein, host biology and baseline microbial ecology.

“Detox supplements prevent cancer.” Not established. Endogenous biotransformation pathways are complex and sometimes double-edged. Exposure reduction and normal organ function are more defensible targets.

“One perfect diet exists for every cancer and every person.” No. Tumour metabolism and host metabolism are heterogeneous. A useful framework must allow individual response and biological trade-offs.

24. What a Prevention-Oriented Metabolic Pattern Looks Like

A prevention-oriented pattern is not defined by a branded diet. It is defined by the biology it produces. The person remains lean enough to limit visceral adipose dysfunction while retaining muscle. Glucose is handled efficiently without chronically high insulin. Meals are satisfying enough that constant snacking is unnecessary. The gut receives enough fermentable substrate to support barrier function. Physical activity maintains cardiorespiratory and mitochondrial capacity. Sleep and light exposure keep circadian signals coherent. Exposure to avoidable carcinogens is low. The body is nutritionally replete enough to run immune, repair and detoxification systems.

For some people, a Mediterranean-style lower-carbohydrate diet can produce this state. For others, a well-formulated ketogenic diet can produce it more effectively. For still others, moderate carbohydrate from intact whole foods works well because insulin sensitivity and activity are high. The common biology is more important than the label.

A practical food architecture

• Protein sufficient to preserve muscle, recovery and immune function.
• Carbohydrate quality prioritised before carbohydrate quantity: minimise refined sugar and flour; use intact, fibre-containing sources according to metabolic tolerance.
• Fats mainly from minimally processed sources, with substantial unsaturated fat and marine omega-3 sources where appropriate.
• A broad range of non-starchy vegetables, herbs and spices; include nuts and seeds when tolerated.
• Fermented foods can be included for variety, but they are not substitutes for dietary fibre.
• Minimal ultra-processed “keto” products; ketosis produced by engineered snack foods is not the same as a nutrient-dense diet.
• Enough total energy to maintain function and lean mass; chronic undernutrition is not metabolic therapy.

25. When Self-Directed Ketosis Is the Wrong Experiment

Because this paper is focused on mechanisms rather than clinical guidelines, it does not provide a medical contraindication list or therapeutic ketogenic protocol. However, one safety principle is essential: nutritional ketosis is a substantial metabolic intervention. People who are pregnant, underweight, have a history of eating disorders, have significant liver or pancreatic disease, have disorders of fat metabolism, or use medicines that can interact with carbohydrate restriction should not treat a general internet protocol as a substitute for individual medical assessment.

The same applies to prolonged fasting. Short overnight fasting is part of normal human physiology. Multi-day fasting produces much larger changes in glucose, ketones, electrolytes, lean tissue and medication response. It should not be converted from an experimental cancer-metabolism concept into a casual prevention ritual.

26. Research Gaps That Matter Most

The metabolic theory has generated testable questions. The next advances will not come from repeating slogans; they will come from resolving heterogeneity.

1. Which tumour genotypes and metabolic phenotypes are genuinely unable to oxidise ketones, and which can use them?
2. Can tumour ketolytic enzyme expression, mitochondrial structure or metabolic flux predict response to ketogenic interventions?
3. What level and duration of host ketosis meaningfully changes human tumour metabolism in vivo?
4. How do ketogenic diets alter the human tumour microbiome and gut microbiome over months rather than weeks?
5. Can a fibre-preserving ketogenic diet maintain short-chain-fatty-acid production while sustaining ketosis?
6. How do glucose, glutamine, lactate, fatty acids and ketones compete or cooperate within different regions of the same human tumour?
7. Which metabolic interventions improve anti-tumour immunity without depriving effector immune cells of essential substrates?
8. Can metabolic phenotyping be integrated with genomics so nutrition is matched to tumour biology rather than prescribed universally?
9. For prevention, do long-term improvements in hyperinsulinaemia and metabolic flexibility lower cancer incidence independently of weight?
10. Which host benefits of carbohydrate restriction come from ketosis itself and which come from weight loss, lower insulin, fewer ultra-processed foods or improved energy balance?

Conclusion: Use the Metabolic Lens Without Becoming Trapped by It

The metabolic view of cancer is consequential because it changes the question from “Which mutation should be attacked?” to “What does this malignant cell need in order to stay alive and proliferate?” That shift reveals glucose, glutamine, lactate, oxygen, redox, mitochondria, immune metabolism and the microenvironment as actionable biology. It also explains why diet and whole-body metabolism can influence cancer biology without being magic cures.

The strongest version of the theory is not that every cancer has one broken engine. It is that malignant cells must continuously solve an energy-and-biomass problem, and they do so through reprogrammed metabolic networks that are shaped by mitochondria, genes and the environment. Some tumours lean heavily on fermentation. Some preserve strong oxidative phosphorylation. Some switch fuels. Some may be vulnerable to ketosis; some may not. The science becomes more useful when this heterogeneity is accepted rather than hidden.

For prevention-oriented functional health, the seven-system model converts that science into a broader host strategy. Build metabolic flexibility. Keep insulin demand low enough that the system remains sensitive. Feed and train muscle. Protect the intestinal barrier and microbiome. Maintain vascular and cardiorespiratory capacity. Keep circadian signals coherent. Support immune defence without chronic inflammation. Reduce avoidable toxic exposure and let endogenous detoxification systems do ordinary physiology well.

That approach is less dramatic than promising that ketosis “starves cancer.” It is also more scientifically defensible. The objective is not to create a hostile body. It is to create a resilient one: a body whose normal cells have flexible energy options, whose immune system is adequately fuelled, whose microbiome remains productive, whose muscle is metabolically active and whose signalling environment is less chronically permissive to dysregulated growth.

Plain-English Glossary

AMPK: An energy sensor inside cells. When cellular energy is low, AMPK shifts metabolism toward energy production and away from expensive growth processes.

Anaplerosis: Refilling the tricarboxylic-acid cycle with carbon so the cycle can continue supporting energy production and biosynthesis.

ATP: The cell’s immediately spendable energy currency.

Autophagy: A cellular recycling process that breaks down damaged or unnecessary components and reuses their building blocks.

Beta-hydroxybutyrate (BHB): The main circulating ketone body during nutritional ketosis; both a fuel and a signalling molecule.

Fermentation: Energy production that does not require the mitochondrial respiratory chain. Glycolysis ending in lactate is the best-known example.

Glutaminolysis: The set of reactions that convert glutamine into metabolites that can support energy, biosynthesis and redox balance.

Glycolysis: The pathway that breaks glucose into pyruvate, producing a small amount of ATP and metabolic intermediates.

GKI: Glucose-ketone index: a ratio of glucose to ketones used in metabolic research. It is not a validated cancer-prevention score.

HDAC: Histone deacetylase: an enzyme that removes acetyl groups from histones and can change which genes are more or less accessible for transcription.

Hyperinsulinaemia: A state in which circulating insulin is chronically higher than required for healthy nutrient handling.

Ketolysis: The process by which cells use ketone bodies for energy.

Ketosis: A state in which the liver produces enough ketones for them to become a meaningful circulating fuel.

Metabolic flexibility: The ability to switch efficiently between fuels such as glucose and fat depending on availability and demand.

Mitochondrial substrate-level phosphorylation: Direct production of a high-energy phosphate molecule inside the mitochondrial metabolic cycle, independent of the respiratory-chain proton gradient.

mTOR: A nutrient- and growth-sensing network that promotes protein synthesis, cell growth and other anabolic processes when resources are available.

NADPH: A reducing molecule used for antioxidant defence and biosynthesis.

NLRP3 inflammasome: A cellular inflammatory sensor that can activate potent inflammatory cytokines.

Oxidative phosphorylation (OxPhos): Mitochondrial ATP production powered by electron transport and a proton gradient.

Redox: The balance of oxidation and reduction reactions, including the control of reactive oxygen species.

Short-chain fatty acids: Small fatty acids, including acetate, propionate and butyrate, produced largely by gut microbes fermenting dietary fibre.

Th17 cells: A type of helper T cell involved in barrier immunity and inflammation.

Tumour microenvironment: The cells, blood vessels, extracellular matrix, immune cells, nutrients, oxygen levels and metabolites surrounding a tumour.

Warburg effect: High glucose uptake and lactate production by cancer cells even when oxygen is available.

References

Only peer-reviewed journal literature is listed here. Books, interviews, videos, medical guidelines and non-peer-reviewed clinical practice materials were not used as evidence for the paper’s scientific conclusions.

Abdelwahab, M.G., Fenton, K.E., Preul, M.C., Rho, J.M., Lynch, A., Stafford, P. and Scheck, A.C. (2012) ‘The ketogenic diet is an effective adjuvant to radiation therapy for the treatment of malignant glioma’, PLoS ONE, 7(5), e36197. https://doi.org/10.1371/journal.pone.0036197.

Altman, B.J., Stine, Z.E. and Dang, C.V. (2016) ‘From Krebs to clinic: glutamine metabolism to cancer therapy’, Nature Reviews Cancer, 16, pp. 619–634. https://doi.org/10.1038/nrc.2016.71.

Ang, Q.Y., Alexander, M., Newman, J.C., Tian, Y., Cai, J., Upadhyay, V., Turnbaugh, J.A., Verdin, E., Hall, K.D., Leibel, R.L., Ravussin, E., Rosenbaum, M., Patterson, A.D. and Turnbaugh, P.J. (2020) ‘Ketogenic diets alter the gut microbiome resulting in decreased intestinal Th17 cells’, Cell, 181(6), pp. 1263–1275.e16. https://doi.org/10.1016/j.cell.2020.04.027.

Augur, Z.M., Doyle, C.M., Li, M., Mukherjee, P. and Seyfried, T.N. (2018) ‘Nontoxic targeting of energy metabolism in preclinical VM-M3 experimental glioblastoma’, Frontiers in Nutrition, 5, 91. https://doi.org/10.3389/fnut.2018.00091.

Bonuccelli, G., Tsirigos, A., Whitaker-Menezes, D., Pavlides, S., Pestell, R.G., Chiavarina, B., Frank, P.G., Flomenberg, N., Howell, A., Martinez-Outschoorn, U.E., Sotgia, F. and Lisanti, M.P. (2010) ‘Ketones and lactate “fuel” tumor growth and metastasis: evidence that epithelial cancer cells use oxidative mitochondrial metabolism’, Cell Cycle, 9(17), pp. 3506–3514. https://doi.org/10.4161/cc.9.17.12731.

Cahill, G.F. Jr. (2006) ‘Fuel metabolism in starvation’, Annual Review of Nutrition, 26, pp. 1–22. https://doi.org/10.1146/annurev.nutr.26.061505.111258.

Chinopoulos, C. and Seyfried, T.N. (2018) ‘Mitochondrial substrate-level phosphorylation as energy source for glioblastoma: review and hypothesis’, ASN Neuro, 10, 1759091418818261. https://doi.org/10.1177/1759091418818261.

DeBerardinis, R.J. and Chandel, N.S. (2016) ‘Fundamentals of cancer metabolism’, Science Advances, 2(5), e1600200. https://doi.org/10.1126/sciadv.1600200.

Demicco, M., Liu, X.-Z., Leithner, K. et al. (2024) ‘Metabolic heterogeneity in cancer’, Nature Metabolism, 6, pp. 18–38. https://doi.org/10.1038/s42255-023-00963-z.

Donohoe, D.R., Collins, L.B., Wali, A., Bigler, R., Sun, W. and Bultman, S.J. (2012) ‘The Warburg effect dictates the mechanism of butyrate-mediated histone acetylation and cell proliferation’, Molecular Cell, 48(4), pp. 612–626. https://doi.org/10.1016/j.molcel.2012.08.033.

Duraj, T., Carrión-Navarro, J., Seyfried, T.N., García-Romero, N. and Ayuso-Sacido, A. (2021) ‘Metabolic therapy and bioenergetic analysis: the missing piece of the puzzle’, Molecular Metabolism, 54, 101389. https://doi.org/10.1016/j.molmet.2021.101389.

Duraj, T. et al. (2024) ‘Clinical research framework proposal for ketogenic metabolic therapy in glioblastoma’, BMC Medicine, 22, 547. https://doi.org/10.1186/s12916-024-03775-4.

Faubert, B., Li, K.Y., Cai, L. et al. (2017) ‘Lactate metabolism in human lung tumors’, Cell, 171(2), pp. 358–371.e9. https://doi.org/10.1016/j.cell.2017.09.019.

Ferrere, G., Tidjani Alou, M., Liu, P. et al. (2021) ‘Ketogenic diet and ketone bodies enhance the anticancer effects of PD-1 blockade’, JCI Insight, 6(2), e145207. https://doi.org/10.1172/jci.insight.145207.

Firdous, J. et al. (2026) ‘Efficacy and safety of ketogenic diet in glioblastoma: an updated systematic review and meta-analysis’, Neurological Sciences, 47, 461. https://doi.org/10.1007/s10072-026-09035-y.

Gallagher, E.J. and LeRoith, D. (2020) ‘Hyperinsulinaemia in cancer’, Nature Reviews Cancer, 20, pp. 629–644. https://doi.org/10.1038/s41568-020-0295-5.

Hanahan, D. (2022) ‘Hallmarks of cancer: new dimensions’, Cancer Discovery, 12(1), pp. 31–46. https://doi.org/10.1158/2159-8290.CD-21-1059.

Hardie, D.G., Ross, F.A. and Hawley, S.A. (2012) ‘AMPK: a nutrient and energy sensor that maintains energy homeostasis’, Nature Reviews Molecular Cell Biology, 13, pp. 251–262. https://doi.org/10.1038/nrm3311.

Hensley, C.T., Faubert, B., Yuan, Q. et al. (2016) ‘Metabolic heterogeneity in human lung tumors’, Cell, 164(4), pp. 681–694. https://doi.org/10.1016/j.cell.2015.12.034.

Hopkins, B.D., Goncalves, M.D. and Cantley, L.C. (2022) ‘Insulin and cancer: a tangled web’, Biochemical Journal, 479(5), pp. 583–607. https://doi.org/10.1042/BCJ20210134.

Hui, S., Ghergurovich, J.M., Morscher, R.J. et al. (2017) ‘Glucose feeds the TCA cycle via circulating lactate’, Nature, 551, pp. 115–118. https://doi.org/10.1038/nature24057.

Jiang, Y. et al. (2021) ‘Five-day water-only fasting decreased metabolic-syndrome risk factors and increased anti-aging biomarkers without toxicity in a clinical trial of normal-weight individuals’, Clinical and Translational Medicine, 11(8), e502. https://doi.org/10.1002/ctm2.502.

Kensler, T.W., Wakabayashi, N. and Biswal, S. (2007) ‘Cell survival responses to environmental stresses via the Keap1-Nrf2-ARE pathway’, Annual Review of Pharmacology and Toxicology, 47, pp. 89–116. https://doi.org/10.1146/annurev.pharmtox.46.120604.141046.

Klement, R.J., Brehm, N. and Sweeney, R.A. (2020) ‘Ketogenic diets in medical oncology: a systematic review with focus on clinical outcomes’, Medical Oncology, 37, 14. https://doi.org/10.1007/s12032-020-1337-2.

Koppel, N., Rekdal, V.M. and Balskus, E.P. (2017) ‘Chemical transformation of xenobiotics by the human gut microbiota’, Science, 356(6344), eaag2770. https://doi.org/10.1126/science.aag2770.

Lee, D.C., Ta, L., Mukherjee, P., Duraj, T. et al. (2024) ‘Amino acid and glucose fermentation maintain ATP content in mouse and human malignant glioma cells’, ASN Neuro, 16(1), 2422268. https://doi.org/10.1080/17590914.2024.2422268.

Liu, G., Tang, J., Zhou, J. and Dong, M. (2024) ‘Short-chain fatty acids play a positive role in colorectal cancer’, Discover Oncology, 15, 425. https://doi.org/10.1007/s12672-024-01313-5.

Mann, E.R., Lam, Y.K. and Uhlig, H.H. (2024) ‘Short-chain fatty acids: linking diet, the microbiome and immunity’, Nature Reviews Immunology, 24, pp. 577–595. https://doi.org/10.1038/s41577-024-01014-8.

Martínez-Reyes, I. and Chandel, N.S. (2021) ‘Cancer metabolism: looking forward’, Nature Reviews Cancer, 21, pp. 669–680. https://doi.org/10.1038/s41568-021-00378-6.

Meidenbauer, J.J., Mukherjee, P. and Seyfried, T.N. (2015) ‘The glucose ketone index calculator: a simple tool to monitor therapeutic efficacy for metabolic management of brain cancer’, Nutrition & Metabolism, 12, 12. https://doi.org/10.1186/s12986-015-0009-2.

Mukherjee, P., Augur, Z.M., Li, M. et al. (2019) ‘Therapeutic benefit of combining calorie-restricted ketogenic diet and glutamine targeting in late-stage experimental glioblastoma’, Communications Biology, 2, 200. https://doi.org/10.1038/s42003-019-0455-x.

Newman, J.C. and Verdin, E. (2014) ‘Ketone bodies as signaling metabolites’, Trends in Endocrinology & Metabolism, 25(1), pp. 42–52. https://doi.org/10.1016/j.tem.2013.09.002.

O’Keefe, S.J.D. (2016) ‘Diet, microorganisms and their metabolites, and colon cancer’, Nature Reviews Gastroenterology & Hepatology, 13, pp. 691–706. https://doi.org/10.1038/nrgastro.2016.165.

Pavlova, N.N. and Thompson, C.B. (2016) ‘The emerging hallmarks of cancer metabolism’, Cell Metabolism, 23(1), pp. 27–47. https://doi.org/10.1016/j.cmet.2015.12.006.

Persiani, M. et al. (2026) ‘Ketogenic diet in the treatment of malignant gliomas: a systematic review’, Nutrients, 18(13), 2166. https://doi.org/10.3390/nu18132166.

Phinney, S.D., Bistrian, B.R., Evans, W.J., Gervino, E. and Blackburn, G.L. (1983) ‘The human metabolic response to chronic ketosis without caloric restriction: preservation of submaximal exercise capability with reduced carbohydrate oxidation’, Metabolism, 32(8), pp. 769–776. https://doi.org/10.1016/0026-0495(83)90106-3.

Pick, R., Wang, C., Zeng, Q., Gül, Z.M. and Scheiermann, C. (2024) ‘Circadian rhythms in anticancer immunity: mechanisms and treatment opportunities’, Annual Review of Immunology, 42, pp. 83–102. https://doi.org/10.1146/annurev-immunol-090122-050842.

Poff, A.M., Ari, C., Arnold, P., Seyfried, T.N. and D’Agostino, D.P. (2014) ‘Ketone supplementation decreases tumor cell viability and prolongs survival of mice with metastatic cancer’, International Journal of Cancer, 135(7), pp. 1711–1720. https://doi.org/10.1002/ijc.28809.

Poff, A.M., Ward, N., Seyfried, T.N., Arnold, P. and D’Agostino, D.P. (2015) ‘Non-toxic metabolic management of metastatic cancer in VM mice: novel combination of ketogenic diet, ketone supplementation, and hyperbaric oxygen therapy’, PLoS ONE, 10(6), e0127407. https://doi.org/10.1371/journal.pone.0127407.

Puchalska, P. and Crawford, P.A. (2017) ‘Multi-dimensional roles of ketone bodies in fuel metabolism, signaling, and therapeutics’, Cell Metabolism, 25(2), pp. 262–284. https://doi.org/10.1016/j.cmet.2016.12.022.

Ravasz, D. et al. (2024) ‘Residual complex I activity and amphidirectional complex II operation support glutamate catabolism through mitochondrial substrate-level phosphorylation in anoxia’, Scientific Reports, 14, 1532. https://doi.org/10.1038/s41598-024-51365-4.

Römer, M., Dörfler, J. and Huebner, J. (2021) ‘The use of ketogenic diets in cancer patients: a systematic review’, Clinical and Experimental Medicine, 21, pp. 501–536. https://doi.org/10.1007/s10238-021-00710-2.

Salido-Bueno, B., Gil-Hernandez, E., Rueda-Ruzafa, L., Gomez-Chica, P., Roman, P. and Cardona, D. (2024) ‘Effects of ketogenic diets on cancer-related variables: a systematic review and meta-analysis of randomised controlled trials’, Nutrition Bulletin, 49(3), pp. 264–277. https://doi.org/10.1111/nbu.12693.

Sepich-Poore, G.D., Zitvogel, L., Straussman, R., Hasty, J., Wargo, J.A. and Knight, R. (2021) ‘The microbiome and human cancer’, Science, 371(6536), eabc4552. https://doi.org/10.1126/science.abc4552.

Seyfried, T.N., Flores, R.E., Poff, A.M. and D’Agostino, D.P. (2014) ‘Cancer as a metabolic disease: implications for novel therapeutics’, Carcinogenesis, 35(3), pp. 515–527. https://doi.org/10.1093/carcin/bgt480.

Seyfried, T.N. (2015) ‘Cancer as a mitochondrial metabolic disease’, Frontiers in Cell and Developmental Biology, 3, 43. https://doi.org/10.3389/fcell.2015.00043.

Seyfried, T.N., Yu, G., Maroon, J.C. and D’Agostino, D.P. (2017) ‘Press-pulse: a novel therapeutic strategy for the metabolic management of cancer’, Nutrition & Metabolism, 14, 19. https://doi.org/10.1186/s12986-017-0178-2.

Seyfried, T.N. and Chinopoulos, C. (2021) ‘Can the mitochondrial metabolic theory explain better the origin and management of cancer than can the somatic mutation theory?’, Metabolites, 11(9), 572. https://doi.org/10.3390/metabo11090572.

Seyfried, T.N., Arismendi-Morillo, G., Zuccoli, G. et al. (2022) ‘Metabolic management of microenvironment acidity in glioblastoma’, Frontiers in Oncology, 12, 968351. https://doi.org/10.3389/fonc.2022.968351.

Seyfried, T.N., Duraj, T. et al. (2023) ‘Ketosis suppression and ageing (KetoSAge): the effects of suppressing ketosis in long-term keto-adapted non-athletic females’, International Journal of Molecular Sciences, 24(21), 15621. https://doi.org/10.3390/ijms242115621.

Seyfried, T.N., Lee, D.C., Duraj, T., Ta, N.L., Mukherjee, P., Kiebish, M., Arismendi-Morillo, G. and Chinopoulos, C. (2025) ‘The Warburg hypothesis and the emergence of the mitochondrial metabolic theory of cancer’, Journal of Bioenergetics and Biomembranes, 57, pp. 57–83. https://doi.org/10.1007/s10863-025-10059-w.

Shimazu, T., Hirschey, M.D., Newman, J. et al. (2013) ‘Suppression of oxidative stress by β-hydroxybutyrate, an endogenous histone deacetylase inhibitor’, Science, 339(6116), pp. 211–214. https://doi.org/10.1126/science.1227166.

Spencer, C.N., McQuade, J.L., Gopalakrishnan, V. et al. (2021) ‘Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response’, Science, 374(6575), pp. 1632–1640. https://doi.org/10.1126/science.aaz7015.

Tong, Y., Gao, W.-Q. and Liu, Y. (2020) ‘Metabolic heterogeneity in cancer: an overview and therapeutic implications’, Biochimica et Biophysica Acta Reviews on Cancer, 1874(2), 188421. https://doi.org/10.1016/j.bbcan.2020.188421.

Vander Heiden, M.G., Cantley, L.C. and Thompson, C.B. (2009) ‘Understanding the Warburg effect: the metabolic requirements of cell proliferation’, Science, 324(5930), pp. 1029–1033. https://doi.org/10.1126/science.1160809.

Volek, J.S., Freidenreich, D.J., Saenz, C. et al. (2016) ‘Metabolic characteristics of keto-adapted ultra-endurance runners’, Metabolism, 65(3), pp. 100–110. https://doi.org/10.1016/j.metabol.2015.10.028.

Wallace, D.C. (2012) ‘Mitochondria and cancer’, Nature Reviews Cancer, 12, pp. 685–698. https://doi.org/10.1038/nrc3365.

White, E. (2015) ‘The role for autophagy in cancer’, Journal of Clinical Investigation, 125(1), pp. 42–46. https://doi.org/10.1172/JCI73941.

Wise, D.R. and Thompson, C.B. (2010) ‘Glutamine addiction: a new therapeutic target in cancer’, Trends in Biochemical Sciences, 35(8), pp. 427–433. https://doi.org/10.1016/j.tibs.2010.05.003.

Xia, S., Lin, R., Jin, L. et al. (2017) ‘Prevention of dietary-fat-fueled ketogenesis attenuates BRAF V600E tumor growth’, Cell Metabolism, 25(2), pp. 358–373. https://doi.org/10.1016/j.cmet.2016.12.010.

Youm, Y.-H., Nguyen, K.Y., Grant, R.W. et al. (2015) ‘The ketone metabolite β-hydroxybutyrate blocks NLRP3 inflammasome-mediated inflammatory disease’, Nature Medicine, 21, pp. 263–269. https://doi.org/10.1038/nm.3804.

Zhang, J., Jia, P.P., Liu, Q.L. et al. (2018) ‘Low ketolytic enzyme levels in tumors predict ketogenic diet responses in cancer cell lines in vitro and in vivo’, Journal of Lipid Research, 59(4), pp. 625–634. https://doi.org/10.1194/jlr.M082040.

Zeng, Y., Guo, Z., Wu, M. et al. (2024) ‘Circadian rhythm regulates the function of immune cells and participates in the development of tumors’, Cell Death Discovery, 10, 199. https://doi.org/10.1038/s41420-024-01960-1.

Zhang, X., Zhao, W., Chen, C. and Zhang, Z. (2021) ‘Extracellular matrix stiffness: new areas affecting cell metabolism’, Frontiers in Oncology, 11, 631991. https://doi.org/10.3389/fonc.2021.631991.

Zitvogel, L., Ma, Y., Raoult, D., Kroemer, G. and Gajewski, T.F. (2018) ‘The microbiome in cancer immunotherapy: diagnostic tools and therapeutic strategies’, Science, 359(6382), pp. 1366–1370. https://doi.org/10.1126/science.aar6918.

Zoncu, R., Efeyan, A. and Sabatini, D.M. (2011) ‘mTOR: from growth signal integration to cancer, diabetes and ageing’, Nature Reviews Molecular Cell Biology, 12, pp. 21–35. https://doi.org/10.1038/nrm3025.

Evidence Map by Question

Mitochondrial origin and function — The literature strongly supports widespread mitochondrial reprogramming in cancer and shows that mitochondrial dysfunction can promote malignant phenotypes. It simultaneously demonstrates that many cancers require functional mitochondria. The universal “respiration is broken in all cancer” claim is therefore not established.

Glucose — Strong mechanistic and human tumour evidence supports high glucose uptake and glycolytic reprogramming in many cancers. Glucose also supplies biosynthetic and redox pathways. Host glucose cannot be eliminated by carbohydrate restriction because endogenous production continues.

Glutamine — Strong mechanistic evidence supports glutamine as a carbon, nitrogen and redox substrate across many cancers. Recent malignant-glioma work supports glutamine-linked ATP maintenance through mitochondrial substrate-level phosphorylation under constrained conditions. Dietary glutamine restriction is not a validated prevention strategy.

Ketogenic adaptation — Strong human evidence establishes the physiology of ketosis and increased fat oxidation. Preclinical evidence supports anti-tumour effects in several models, while other models show neutral or tumour-promoting effects depending on genotype and ketolytic capacity. Human cancer-outcome evidence remains insufficient for universal claims.

Microbiome — Strong evidence shows that ketogenic diets can alter gut microbial ecology and immune signalling. Strong mechanistic evidence links microbial metabolites to barrier integrity, inflammation and colorectal-cancer biology. The ideal microbiome-supportive ketogenic pattern has not been established in long-term cancer-prevention trials.

Seven functional systems — Each system maps onto established biology, but the seven-part grouping itself is a practical functional-health framework rather than a validated oncology model. It should be used to ask better questions, not to generate a cancer-risk score.

Final research note The most defensible conclusion from the present literature is neither “keto cures cancer” nor “metabolism is irrelevant.” Metabolic reprogramming is central to cancer biology, but tumours are heterogeneous and adaptive. Prevention-oriented metabolic health should therefore strengthen the whole host system rather than pursue extreme restriction around a single fuel.